Compare Stocks: LRMR, FBRX, BCAX, and NVAX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$23.17 -0.7%	$26.48	$10.30 ▼ $30.99	$1.54B	-0.82	598,424 shs	296,877 shs
FBRX Forte Biosciences	$76.99	$60.99	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A
LRMR Larimar Therapeutics	$3.83	$3.89	$2.71 ▼ $6.42	$397.87M	0.74	972,941 shs	391,890 shs
NVAX Novavax	$10.22 -1.2%	$8.59	$6.20 ▼ $11.97	$1.71B	2.45	5.23 million shs	5.12 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	-0.73%	-1.11%	-10.51%	+15.85%	+93.08%
FBRX Forte Biosciences	0.00%	0.00%	+0.50%	+366.04%	+595.48%
LRMR Larimar Therapeutics	0.00%	-4.49%	-6.59%	+20.82%	-2.79%
NVAX Novavax	-1.16%	+10.37%	+32.73%	+7.69%	+38.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$23.17 -0.7%	$26.48	$10.30 ▼ $30.99	$1.54B	-0.82	598,424 shs	296,877 shs
FBRX Forte Biosciences	$76.99	$60.99	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A
LRMR Larimar Therapeutics	$3.83	$3.89	$2.71 ▼ $6.42	$397.87M	0.74	972,941 shs	391,890 shs
NVAX Novavax	$10.22 -1.2%	$8.59	$6.20 ▼ $11.97	$1.71B	2.45	5.23 million shs	5.12 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	-0.73%	-1.11%	-10.51%	+15.85%	+93.08%
FBRX Forte Biosciences	0.00%	0.00%	+0.50%	+366.04%	+595.48%
LRMR Larimar Therapeutics	0.00%	-4.49%	-6.59%	+20.82%	-2.79%
NVAX Novavax	-1.16%	+10.37%	+32.73%	+7.69%	+38.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	2.80	Moderate Buy	$32.64	40.86% Upside
FBRX Forte Biosciences	2.00	Hold	$71.67	-6.91% Downside
LRMR Larimar Therapeutics	3.10	Buy	$11.67	204.61% Upside
NVAX Novavax	2.33	Hold	$14.00	36.99% Upside

Current Analyst Ratings Breakdown

Latest LRMR, FBRX, BCAX, and NVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	BCAX Bicara Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$35.00
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $33.00
8/12/2026	BCAX Bicara Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/12/2026	BCAX Bicara Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/12/2026	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$16.00 ➝ $23.00
8/12/2026	BCAX Bicara Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $39.00
8/11/2026	BCAX Bicara Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$37.00 ➝ $39.00
8/6/2026	NVAX Novavax	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.08 per share	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.66 per share	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$1.23 per share	N/A
NVAX Novavax	$1.12B	1.50	$3.46 per share	2.95	($1.16) per share	-8.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$137.95M	-$3.10	N/A	N/A	N/A	N/A	-41.49%	-38.59%	11/9/2026 (Estimated)
FBRX Forte Biosciences	-$69.38M	-$4.65	N/A	N/A	N/A	N/A	-94.82%	-77.68%	11/13/2026 (Estimated)
LRMR Larimar Therapeutics	-$165.67M	-$1.95	N/A	N/A	N/A	N/A	-137.39%	-97.65%	11/5/2026 (Estimated)
NVAX Novavax	$440.30M	-$1.52	N/A	N/A	N/A	-59.87%	-14.82%	-13.35%	11/5/2026 (Estimated)

Latest LRMR, FBRX, BCAX, and NVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	FBRX Forte Biosciences	-$0.9950	-$0.97	+$0.0250	-$0.97	N/A	N/A
8/11/2026	Q2 2026	BCAX Bicara Therapeutics	-$0.8198	-$0.82	-$0.0002	-$0.82	N/A	N/A
8/6/2026	Q2 2026	NVAX Novavax	-$0.3798	-$0.32	+$0.0598	-$0.32	$52.51 million	$56.70 million
8/4/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.3815	-$0.30	+$0.0815	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	11.59	11.59
FBRX Forte Biosciences	N/A	10.01	10.01
LRMR Larimar Therapeutics	N/A	4.70	4.70
NVAX Novavax	N/A	2.33	2.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
FBRX Forte Biosciences	77.63%
LRMR Larimar Therapeutics	91.92%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	13.80%
FBRX Forte Biosciences	4.40%
LRMR Larimar Therapeutics	4.00%
NVAX Novavax	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	66.17 million	57.04 million	N/A
FBRX Forte Biosciences	5	21.23 million	20.30 million	Optionable
LRMR Larimar Therapeutics	30	103.88 million	99.73 million	Optionable
NVAX Novavax	1,990	164.95 million	162.31 million	Optionable

LRMR, FBRX, BCAX, and NVAX Headlines

Recent News About These Companies

1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds

1 hour ago | finance.yahoo.com

NVAX stock holds near 10 dollars as new institutional money arrives

September 4 at 5:42 PM | ad-hoc-news.deA

Bank of New York Mellon Corp Makes New $8 Million Investment in Novavax, Inc. $NVAX

September 4 at 3:27 AM | marketbeat.com

Novavax to Participate in September Investor Conferences

September 2 at 7:14 PM | finance.yahoo.com

Novavax to Participate in September Investor Conferences

September 2 at 5:00 PM | prnewswire.com

Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor

September 2 at 9:30 AM | benzinga.com

What's going on with Novavax stock?

September 1, 2026 | msn.com

Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?

September 1, 2026 | 247wallst.com

Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?

September 1, 2026 | 247wallst.com

What's Going On With Novavax Stock?

September 1, 2026 | benzinga.com

Novavax (NASDAQ:NVAX) Shares Up 5.3% - Here's What Happened

August 31, 2026 | marketbeat.com

Novavax Stock Climbs Monday: What's Going On?

August 31, 2026 | benzinga.com

Research Analysts Set Expectations for Novavax Q3 Earnings

August 30, 2026 | americanbankingnews.com

How Expanded Nuvaxovid Royalties and Partner-led Execution Could Shape Novavax’s (NVAX) Investment Narrative

August 29, 2026 | finance.yahoo.com

Has Novavax (NVAX) Fallen Far Enough To Look Cheap?

August 29, 2026 | finance.yahoo.com

Novavax (NVDA) Following Updated Nuvaxovid Approval Faces A Wide Fair Value Debate

August 29, 2026 | finance.yahoo.com

Novavax's Nuvaxovid Approved in US, EU, Japan for 2026-2027 Season

August 28, 2026 | finance.yahoo.com

NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open

August 28, 2026 | stocktwits.comS

Novavax's XFG-Adapted Nuvaxovid Approved In U.S., EU, Japan For 2026-2027 Season

August 28, 2026 | rttnews.com

Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season

August 28, 2026 | finance.yahoo.com

Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season

August 28, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR, FBRX, BCAX, and NVAX Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$23.17 -0.17 (-0.73%)

As of 09/4/2026 04:00 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Forte Biosciences NASDAQ:FBRX

$76.99 0.00 (0.00%)

As of 08/27/2026

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Larimar Therapeutics NASDAQ:LRMR

$3.83 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Novavax NASDAQ:NVAX

$10.22 -0.12 (-1.16%)

As of 09/4/2026 04:00 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LRMR, FBRX, BCAX, and NVAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LRMR, FBRX, BCAX, and NVAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LRMR, FBRX, BCAX, and NVAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR, FBRX, BCAX, and NVAX Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Forte Biosciences NASDAQ:FBRX

Larimar Therapeutics NASDAQ:LRMR

Novavax NASDAQ:NVAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LRMR, FBRX, BCAX, and NVAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LRMR, FBRX, BCAX, and NVAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LRMR, FBRX, BCAX, and NVAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR, FBRX, BCAX, and NVAX Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Forte Biosciences NASDAQ:FBRX

Larimar Therapeutics NASDAQ:LRMR

Novavax NASDAQ:NVAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools